KalVista Pharmaceuticals, Inc. (KALV): Price and Financial Metrics
GET POWR RATINGS... FREE!
KALV POWR Grades
- Value is the dimension where KALV ranks best; there it ranks ahead of 49.95% of US stocks.
- The strongest trend for KALV is in Stability, which has been heading down over the past 31 weeks.
- KALV's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
KALV Stock Summary
- The ratio of debt to operating expenses for KalVista Pharmaceuticals Inc is higher than it is for about only 6.46% of US stocks.
- With a price/sales ratio of 181.29, KalVista Pharmaceuticals Inc has a higher such ratio than 97.42% of stocks in our set.
- As for revenue growth, note that KALV's revenue has grown -67.57% over the past 12 months; that beats the revenue growth of just 3.82% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to KalVista Pharmaceuticals Inc are MRUS, GSIT, AUTL, CERC, and AMSC.
- Visit KALV's SEC page to see the company's official filings. To visit the company's web site, go to www.kalvista.com.
KALV Stock Price Chart Interactive Chart >
KALV Price/Volume Stats
|Current price||$28.03||52-week high||$45.00|
|Prev. close||$29.91||52-week low||$9.62|
|Day high||$30.15||Avg. volume||700,169|
|50-day MA||$26.12||Dividend yield||N/A|
|200-day MA||$22.03||Market Cap||684.58M|
KalVista Pharmaceuticals, Inc. (KALV) Company Bio
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The companys product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is based in Cambridge, Massachusetts.
KALV Latest News Stream
|Loading, please wait...|
KALV Latest Social Stream
View Full KALV Social Stream
Latest KALV News From Around the Web
Below are the latest news stories about KalVista Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALV as an investment opportunity.
Form 8-K KalVista Pharmaceuticals For: Jun 05 StreetInsider.com
KalVista Pharmaceuticals (KALV) announces clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema ((HAE)) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop. An analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity in Phase 2 cross-over trial in patients with HAE type I...
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
- KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. ET. A live webcast of the presentation will be available on the Companys website at www.kalvista.com. An audio ar
KALV Price Returns
Continue Researching KALVWant to see what other sources are saying about KalVista Pharmaceuticals Inc's financials and stock price? Try the links below:
KalVista Pharmaceuticals Inc (KALV) Stock Price | Nasdaq
KalVista Pharmaceuticals Inc (KALV) Stock Quote, History and News - Yahoo Finance
KalVista Pharmaceuticals Inc (KALV) Stock Price and Basic Information | MarketWatch